<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults: Clinical features, evaluation, and diagnosis
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults: Clinical features, evaluation, and diagnosis
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults: Clinical features, evaluation, and diagnosis
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Irl B Hirsch, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Michael Emmett, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            David M Nathan, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Katya Rubinow, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jul 27, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Diabetic ketoacidosis (DKA) and hyperosmolar hyperglycemic state (HHS, also known as hyperosmotic hyperglycemic nonketotic state [HHNK]) are two of the most serious acute complications of diabetes. DKA is characterized by ketoacidosis and hyperglycemia, while HHS usually has more severe hyperglycemia but no ketoacidosis  (
         <a class="graphic graphic_table graphicRef72111" href="/z/d/graphic/72111.html" rel="external">
          table 1
         </a>
         ). Each represents an extreme in the spectrum of hyperglycemia.
        </p>
        <p>
         The precipitating factors, clinical features, evaluation, and diagnosis of DKA and HHS in adults will be reviewed here. The epidemiology, pathogenesis, and treatment of these disorders are discussed separately. DKA in children is also reviewed separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/1794.html" rel="external">
          "Diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults: Epidemiology and pathogenesis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/1795.html" rel="external">
          "Diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults: Treatment"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5809.html" rel="external">
          "Diabetic ketoacidosis in children: Clinical features and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5808.html" rel="external">
          "Diabetic ketoacidosis in children: Treatment and complications"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          PRECIPITATING FACTORS
         </span>
         <span class="headingEndMark">
          —
         </span>
         A precipitating event can usually be identified in patients with diabetic ketoacidosis (DKA) or hyperosmolar hyperglycemic state (HHS)  (
         <a class="graphic graphic_table graphicRef64374" data-inline-graphics="64374" href="/z/d/graphic/64374.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid1">
          1-3
         </a>
         ]. The most common events are infection (often pneumonia or urinary tract infection) and discontinuation of or inadequate insulin therapy. Compromised water intake due to underlying medical conditions, particularly in older patients, can promote the development of severe dehydration and HHS [
         <a href="#rid3">
          3-5
         </a>
         ].
        </p>
        <p>
         Other conditions and factors associated with DKA and HHS include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Acute major illnesses such as myocardial infarction, cerebrovascular accident, sepsis, or pancreatitis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         New-onset type 1 diabetes, in which DKA is a common presentation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In established type 1 diabetes, omission of insulin in setting of gastroenteritis when patient mistakenly stops insulin because of reduced oral intake.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Drugs that affect carbohydrate metabolism, including glucocorticoids, higher-dose thiazide diuretics, sympathomimetic agents (eg,
         <a class="drug drug_general" data-topicid="9380" href="/z/d/drug information/9380.html" rel="external">
          dobutamine
         </a>
         and
         <a class="drug drug_general" data-topicid="9977" href="/z/d/drug information/9977.html" rel="external">
          terbutaline
         </a>
         ) [
         <a href="#rid6">
          6
         </a>
         ], and second-generation "atypical" antipsychotic agents [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sodium-glucose co-transporter 2 (SGLT2) inhibitors, mostly used in type 2 diabetes but also used off-label in type 1 diabetes. There is a complex physiology that has resulted in reports of DKA in both types of diabetes [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cocaine use, which has been associated with recurrent DKA [
         <a href="#rid9">
          9,10
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Psychological problems associated with eating disorders and purposeful insulin omission, particularly in young patients with type 1 diabetes [
         <a href="#rid11">
          11
         </a>
         ]. Factors that may lead to insulin omission in younger patients include fear of weight gain, fear of hypoglycemia, rebellion from authority, and the stress of chronic disease.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Poor compliance with the insulin regimen.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Malfunction of continuous subcutaneous insulin infusion (CSII) devices, which was initially reported in the early 1980s [
         <a href="#rid12">
          12
         </a>
         ]. Pump malfunction is now uncommon, but system failure due to blockage or leakage in the syringe or the infusion set or connectors, causing an interruption of infusion flow, can lead to DKA. The frequency of DKA with pump therapy, however, appears to be no different in children from that with multiple daily injections of insulin [
         <a href="#rid13">
          13
         </a>
         ]. Fast-acting aspart and lispro-aabc are both approved with some, but not all, insulin pumps in the United States (U-200 lispro-aabc is not approved with any pump). There are no data to know if these faster insulins results in more frequent or severe DKA should there be an interruption of insulin flow.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h1">
          CLINICAL PRESENTATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Diabetic ketoacidosis (DKA) usually evolves rapidly, over a 24-hour period. In contrast, symptoms of hyperosmolar hyperglycemic state (HHS) develop more insidiously with polyuria, polydipsia, and weight loss, often persisting for several days before hospital admission.
        </p>
        <p>
         The earliest symptoms of marked hyperglycemia are polyuria, polydipsia, and weight loss. As the degree or duration of hyperglycemia progresses, neurologic symptoms, including lethargy, focal signs, and obtundation, can develop. This can progress to coma in later stages. Neurologic symptoms are most common in HHS, while hyperventilation and abdominal pain are primarily limited to patients with DKA.
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h2">
          Neurologic symptoms
         </span>
         <span class="headingEndMark">
          —
         </span>
         Neurologic deterioration primarily occurs in patients with an effective plasma osmolality (Posm) above 320 to 330 mosmol/kg [
         <a href="#rid1">
          1,14-16
         </a>
         ] (see
         <a class="local">
          'Plasma osmolality'
         </a>
         below). Mental obtundation and coma are more frequent in HHS than DKA because of the usually greater degree of hyperosmolality in HHS  (
         <a class="graphic graphic_table graphicRef72111" href="/z/d/graphic/72111.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid17">
          17
         </a>
         ]. In addition, some patients with HHS have focal neurologic signs (hemiparesis or hemianopsia) and/or seizures [
         <a href="#rid17">
          17-21
         </a>
         ]. Mental obtundation may occur in patients with DKA, who have lesser degrees of hyperosmolality, when severe acidosis exists [
         <a href="#rid22">
          22
         </a>
         ]. However, stupor or coma in diabetic patients with an effective Posm lower than 320 mosmol/kg demands immediate consideration of other causes of the mental status change.
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h2">
          Abdominal pain in DKA
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with diabetic ketoacidosis (DKA) may present with nausea, vomiting, and abdominal pain; although more common in children, these symptoms can be seen in adults [
         <a href="#rid23">
          23
         </a>
         ]. Abdominal pain is unusual in HHS. In a review of 189 consecutive episodes of DKA and 11 episodes of HHS, abdominal pain was reported in 46 percent of patients with DKA compared with none of the patients with HHS [
         <a href="#rid24">
          24
         </a>
         ]. Abdominal pain was associated with the severity of the metabolic acidosis (occurring in 86 percent of those with a serum bicarbonate ≤5 mEq/L but only 13 percent of those with a serum bicarbonate ≥15 mEq/L) but did not correlate with the severity of hyperglycemia or dehydration.
        </p>
        <p>
         Possible causes of abdominal pain include delayed gastric emptying and ileus induced by the metabolic acidosis and associated electrolyte abnormalities [
         <a href="#rid1">
          1
         </a>
         ]. Other causes for abdominal pain, such as pancreatitis, should be sought when they occur in the absence of severe metabolic acidosis and when they persist after the resolution of ketoacidosis.
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h2">
          Physical examination
         </span>
         <span class="headingEndMark">
          —
         </span>
         Signs of volume depletion are common in both DKA and HHS and include decreased skin turgor, dry axillae and oral mucosa, low jugular venous pressure, tachycardia, and, if severe, hypotension. Neurologic findings, noted above, also may be seen, particularly in patients with HHS. (See
         <a class="local">
          'Neurologic symptoms'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/2298.html" rel="external">
          "Etiology, clinical manifestations, and diagnosis of volume depletion in adults"
         </a>
         .)
        </p>
        <p>
         Patients with DKA may have a fruity odor (due to exhaled acetone; this is similar to the scent of nail polish remover) and deep respirations reflecting the compensatory hyperventilation (called Kussmaul respirations).
        </p>
        <p class="headingAnchor" id="H6003656">
         <span class="h1">
          DIAGNOSTIC EVALUATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Both diabetic ketoacidosis (DKA) and hyperosmolar hyperglycemic state (HHS) are medical emergencies that require prompt recognition and management  (
         <a class="graphic graphic_table graphicRef57723" data-inline-graphics="57723" href="/z/d/graphic/57723.html" rel="external">
          table 3
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H6004079">
         <span class="h2">
          Initial evaluation
         </span>
         <span class="headingEndMark">
          —
         </span>
         The initial evaluation of patients with hyperglycemic crises should include assessment of cardiorespiratory status, volume status, and mental status. The initial history and rapid but careful physical examination should focus on:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Airway, breathing, and circulation (ABC) status
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Mental status
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Possible precipitating events (eg, source of infection, myocardial infarction)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Volume status
        </p>
        <p>
        </p>
        <p>
         The initial laboratory evaluation of a patient with suspected DKA or HHS should include determination of:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Serum glucose
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Serum electrolytes (with calculation of the anion gap), blood urea nitrogen (BUN), and plasma creatinine
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Complete blood count (CBC) with differential
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Urinalysis and urine ketones by dipstick
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Plasma osmolality (Posm)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Serum beta-hydroxybutyrate (if urine ketones are present)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Arterial blood gas if the serum bicarbonate is substantially reduced or hypoxia is suspected
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Electrocardiogram
        </p>
        <p>
        </p>
        <p>
         Additional testing, such as cultures of urine, sputum, and blood, serum lipase and amylase, and chest radiograph should be performed on a case-by-case basis. Infection (most commonly pneumonia and urinary tract infection) is a common precipitating event. Thus, cultures should be obtained if there are suggestive clinical findings. Recognize that infection may exist in the absence of fever in these patients [
         <a href="#rid25">
          25-27
         </a>
         ]. In the United States, patients hospitalized with DKA or HHS are routinely tested for coronavirus 2019 (COVID-19). (See
         <a class="medical medical_review" href="/z/d/html/128127.html" rel="external">
          "COVID-19: Issues related to diabetes mellitus in adults", section on 'Clinical presentations'
         </a>
         .)
        </p>
        <p>
         Measurement of glycated hemoglobin (A1C) may be useful in determining whether the acute episode is the culmination of an evolutionary process in previously undiagnosed or poorly controlled diabetes or a truly acute episode in an otherwise well-controlled patient.
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h2">
          Laboratory findings
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hyperglycemia and hyperosmolality are the two primary laboratory findings in patients with DKA or HHS; patients with DKA also have a high anion gap metabolic acidosis  (
         <a class="graphic graphic_table graphicRef72111" href="/z/d/graphic/72111.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p>
         A variety of other laboratory tests may be affected. The impact of hyperglycemia, insulin deficiency, osmotic diuresis, and fluid intake in each individual patient leads to variable laboratory findings, depending upon the relative importance of these factors.
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h3">
          Serum glucose
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Classic presentation
         </strong>
         – The serum glucose concentration may exceed 1000 mg/dL (56 mmol/L) in HHS [
         <a href="#rid14">
          14,28
         </a>
         ], but it is generally less than 800 mg/dL (44 mmol/L) and often in the 350 to 500 mg/dL (19.4 to 27.8 mmol/L) range in DKA [
         <a href="#rid15">
          15,28
         </a>
         ]. The mechanism underlying the hyperglycemia in DKA and HHS is reviewed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/1794.html" rel="external">
          "Diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults: Epidemiology and pathogenesis", section on 'Hyperglycemia'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Euglycemic DKA
         </strong>
         – Euglycemic DKA, in which the serum glucose is normal or near normal, has been described, particularly in patients with poor oral intake, treatment with insulin prior to arrival in the emergency department, in pregnant women, and with sodium-glucose co-transporter 2 (SGLT2) inhibitors [
         <a href="#rid8">
          8,29-32
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         When SGLT2 inhibitors block the sodium-glucose co-transporter 2, the resulting glucosuria can minimize or prevent the development of hyperglycemia, despite very low insulin levels/activity and development of ketoacidosis. SGLT2 inhibitors and their adverse effects are reviewed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/109245.html" rel="external">
          "Sodium-glucose cotransporter 2 inhibitors for the treatment of hyperglycemia in type 2 diabetes mellitus", section on 'Diabetic ketoacidosis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Patients with euglycemic diabetic ketoacidosis generally require both insulin and glucose to reverse the ketoacidosis. (See
         <a class="medical medical_review" href="/z/d/html/1795.html" rel="external">
          "Diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults: Treatment", section on 'Fluid replacement'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1795.html" rel="external">
          "Diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults: Treatment", section on 'Insulin'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h3">
          Serum ketones
         </span>
         <span class="headingEndMark">
          —
         </span>
         Three ketone bodies are produced and accumulate in DKA: acetoacetic acid, which is the only one that is a true ketoacid; beta-hydroxybutyric acid (a hydroxyacid formed by the reduction of acetoacetic acid); and acetone, which is derived from the decarboxylation of acetoacetic acid. Acetone is a true ketone, not an acid. Testing for serum ketones is generally performed if urine testing is positive. Urine ketone bodies are detected with
         <a class="drug drug_general" data-topicid="9707" href="/z/d/drug information/9707.html" rel="external">
          nitroprusside
         </a>
         tests, while serum ketones can be detected with either a nitroprusside test or by direct assay of beta-hydroxybutyrate levels. Direct assay of beta-hydroxybutyrate levels is preferred, particularly for monitoring response to therapy. (See
         <a class="medical medical_review" href="/z/d/html/1795.html" rel="external">
          "Diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults: Treatment", section on 'Monitoring'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3174363">
         <span class="h4">
          Nitroprusside testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         This chemical develops a purple color in the presence of acetoacetic acid (and to a much lesser degree, acetone). Urine dipstick testing with
         <a class="drug drug_general" data-topicid="9707" href="/z/d/drug information/9707.html" rel="external">
          nitroprusside
         </a>
         tablets or reagent sticks is widely utilized, and results are available within minutes.
        </p>
        <p>
         Although semiquantitative serum ketone testing with
         <a class="drug drug_general" data-topicid="9707" href="/z/d/drug information/9707.html" rel="external">
          nitroprusside
         </a>
         was the major methodology used for detecting elevated blood ketoacid and acetone levels for many years, it has now been replaced by direct measurement of serum beta-hydroxybutyrate levels.
        </p>
        <p class="headingAnchor" id="H3174381">
         <span class="h4">
          Direct measurement of serum beta-hydroxybutyrate
         </span>
         <span class="headingEndMark">
          —
         </span>
         The serum
         <a class="drug drug_general" data-topicid="9707" href="/z/d/drug information/9707.html" rel="external">
          nitroprusside
         </a>
         test for ketone bodies has been largely replaced by direct assays for beta-hydroxybutyrate [
         <a href="#rid33">
          33
         </a>
         ]. Several beta-hydroxybutyrate assay instruments are commercially available [
         <a href="#rid34">
          34-37
         </a>
         ]. Direct assays for serum beta-hydroxybutyrate eliminate the problems associated with nitroprusside testing (eg, false positives and false negatives). One limitation of most of these direct assays, however, is that beta-hydroxybutyrate is not quantitated above a level of 6 mEq/L. An ideal assay for "ketoacids" would measure the concentrations of both acetoacetate and beta-hydroxybutyrate.
        </p>
        <p>
         Point-of-care bedside analyzers to measure capillary blood beta-hydroxybutyrate are becoming increasingly available [
         <a href="#rid38">
          38,39
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h3">
          Anion gap metabolic acidosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         The serum anion gap is calculated as follows:
        </p>
        <p>
         Serum anion gap = Serum sodium - (serum chloride + bicarbonate)
        </p>
        <p>
         By convention, it is the actual measured plasma sodium concentration and not the sodium concentration corrected for the simultaneous glucose concentration that is used for this calculation.
        </p>
        <p>
         The serum bicarbonate concentration in DKA is usually moderately to markedly reduced. In contrast, the serum bicarbonate concentration is normal or only mildly reduced in HHS  (
         <a class="graphic graphic_table graphicRef72111" href="/z/d/graphic/72111.html" rel="external">
          table 1
         </a>
         ). Patients with DKA usually present with a serum anion gap greater than 20 mEq/L (reference range approximately 3 to 10 mEq/L). In patients with DKA, the elevated anion gap metabolic acidosis is caused by the accumulation of beta-hydroxybutyric and acetoacetic acids. However, the increase in anion gap is variable, being determined by several factors: the rate and duration of ketoacid production, the rate of metabolism of the ketoacids and their loss in the urine, and the volume of distribution of the ketoacid anions. (See
         <a class="medical medical_review" href="/z/d/html/1794.html" rel="external">
          "Diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults: Epidemiology and pathogenesis", section on 'Anion gap metabolic acidosis'
         </a>
         .)
        </p>
        <p>
         Compensatory hyperventilation reduces the partial pressure of carbon dioxide (CO
         <sub>
          2
         </sub>
         ) and mitigates the fall in arterial pH. However, severe ketoacidosis can reduce the pH below 7, especially if hyperventilation is compromised.
        </p>
        <p class="headingAnchor" id="H4564954">
         <span class="h3">
          Plasma osmolality
         </span>
         <span class="headingEndMark">
          —
         </span>
         Plasma osmolality (Posm) is always elevated in patients with HHS but less so with DKA  (
         <a class="graphic graphic_table graphicRef72111" href="/z/d/graphic/72111.html" rel="external">
          table 1
         </a>
         ). The typical total body deficits of water and electrolytes in DKA and HHS are compared in a table  (
         <a class="graphic graphic_table graphicRef76060" href="/z/d/graphic/76060.html" rel="external">
          table 4
         </a>
         ). In patients with HHS, the effective Posm is typically &gt;320 mosmol/kg (reference range approximately 275 to 295 mosmol/kg).
        </p>
        <p>
         Effective Posm (in mosmol/kg) is the portion of total osmolality that is generated by sodium salts and glucose (and, if present,
         <a class="drug drug_general" data-topicid="9587" href="/z/d/drug information/9587.html" rel="external">
          mannitol
         </a>
         or sucrose). Effective osmoles do not penetrate most cell membranes and can cause movement of water across membranes to achieve osmolal equilibrium. Effective Posm does not include "ineffective" osmoles, such as urea, because urea is rapidly permeable across most cell membranes and its accumulation does not induce major water shifts between the intracellular spaces (including the brain) and the extracellular water space [
         <a href="#rid40">
          40
         </a>
         ].
        </p>
        <p>
         Effective osmolality can be estimated with either of the following equations, depending upon the units for sodium (Na) and glucose:
        </p>
        <p class="bulletIndent1">
         Effective Posm = [2 x Na (mEq/L)] + [glucose (mg/dL) ÷ 18]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Effective Posm = [2 x Na (mmol/L)] + glucose (mmol/L)
        </p>
        <p>
        </p>
        <p>
         The Na concentration in these equations is the actual measured plasma Na concentration and not the corrected Na concentration. The Na is multiplied by two to account for the osmotic contribution of sodium's accompanying anions (primarily chloride and bicarbonate). Eighteen is a factor to convert glucose units from mg/dL into mmol/L.
        </p>
        <p>
         If the Posm is measured, using a freezing point reduction osmometer, the result is the total osmolality. Because effective osmolality excludes urea osmoles (BUN), it can be estimated as:
        </p>
        <p class="bulletIndent1">
         Effective Posm = Measured Posm - [BUN (mg/dL) ÷ 2.8]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Effective Posm = Measured Posm - BUN (mmol/L)
        </p>
        <p>
        </p>
        <p>
         2.8 is a factor to convert urea concentration from units of mg/dL into mmol/L.
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h3">
          Serum sodium
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most patients with DKA and HHS are mildly hyponatremic [
         <a href="#rid41">
          41
         </a>
         ]. However, patients with HHS who have a marked osmotic diuresis may present with a normal or even elevated serum Na concentration, despite a markedly elevated serum glucose concentration that can exceed 1000 mg/dL (56 mmol/L) [
         <a href="#rid42">
          42
         </a>
         ]. These patients have a markedly elevated effective Posm and often have neurologic symptoms that can include seizures and coma (see
         <a class="local">
          'Neurologic symptoms'
         </a>
         above). Inadequate water intake contributes to the hyperosmolality and is a particular problem in hot weather and in older individuals who may have an impaired thirst mechanism [
         <a href="#rid43">
          43
         </a>
         ].
        </p>
        <p>
         The measured serum Na concentration in uncontrolled diabetes mellitus is variable because of the interaction of multiple factors, some that lower Na concentration and others that raise it. The increase in Posm created by hyperglycemia pulls water out of the cells, and this reduces the plasma Na concentration. Physiologic calculations suggest that, in the absence of urine losses, the serum Na concentration should fall by approximately 1.6 mEq/L for each 100 mg/100 mL (5.5 mmol/L) increase in glucose concentration, but subsequent studies in experimental subjects and patients found a higher ratio. We use the following ratio: The Na concentration will fall by approximately 2 mEq/L for each 100 mg/100 mL (5.5 mmol/L) increase in glucose concentration. The "corrected" Na concentration can then be approximated by adding 2 mEq/L to the plasma Na concentration for each 100 mg/100 mL (5.5 mmol/L) increase above normal in glucose concentration (
         <a class="calc calc_professional" href="/z/d/html/97114.html" rel="external">
          calculator 1
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/1794.html" rel="external">
          "Diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults: Epidemiology and pathogenesis", section on 'Plasma osmolality and sodium'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1795.html" rel="external">
          "Diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults: Treatment", section on 'Fluid replacement'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H17">
         <span class="h4">
          Pseudohyponatremia/pseudohyperchloremia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Some patients with uncontrolled diabetes develop marked hyperlipidemia and have lactescent serum. This can create electrolyte artifacts when certain analyzers are utilized. Hyperlipidemia will displace water and thereby reduce the plasma water phase fraction below its normal 93 percent. If any step in the analysis requires an exact volume of plasma (or serum), then a reduced amount of water (and electrolyte) will be analyzed. This can result in "pseudohyponatremia." This artifact occurs with any flame photometric analysis and most indirect potentiometric or ion selective electrode methods. However, direct potentiometry analytical methods are generally not susceptible to this artifact [
         <a href="#rid44">
          44-46
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2354.html" rel="external">
          "Diagnostic evaluation of adults with hyponatremia"
         </a>
         .)
        </p>
        <p>
         However, hyperlipidemia can also have an opposite artifactual effect on the chloride concentration when certain chloride analyzers are employed, generating marked pseudohyperchloremia [
         <a href="#rid47">
          47
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2347.html" rel="external">
          "Serum anion gap in conditions other than metabolic acidosis", section on 'Negative serum anion gap'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h3">
          Serum potassium
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients presenting with DKA or HHS have a potassium deficit that averages 300 to 600 mEq  (
         <a class="graphic graphic_table graphicRef76060" href="/z/d/graphic/76060.html" rel="external">
          table 4
         </a>
         ) [
         <a href="#rid41">
          41,48,49
         </a>
         ]. A number of factors contribute to this deficit, particularly increased urinary losses due both to the glucose osmotic diuresis and to the excretion of potassium ketoacid anion salts. Despite these total body potassium deficits, hypokalemia is observed in only approximately 5 percent of cases [
         <a href="#rid50">
          50,51
         </a>
         ]. The serum potassium concentration is usually normal or, in one-third of patients, elevated on admission [
         <a href="#rid28">
          28,41,52
         </a>
         ]. This is due to a shift of potassium from intracellular fluid to extracellular fluid (ECF) caused by hyperosmolality and insulin deficiency [
         <a href="#rid6">
          6,40,41
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1794.html" rel="external">
          "Diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults: Epidemiology and pathogenesis", section on 'Potassium'
         </a>
         .)
        </p>
        <p>
         Insulin therapy shifts potassium into cells and lowers the potassium concentration. This may cause severe hypokalemia, particularly in patients who present with a normal or low serum potassium concentration [
         <a href="#rid49">
          49
         </a>
         ]. Careful monitoring and timely administration of potassium supplementation are essential. (See
         <a class="medical medical_review" href="/z/d/html/1795.html" rel="external">
          "Diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults: Treatment", section on 'Potassium replacement'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H19">
         <span class="h3">
          Serum phosphate
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with uncontrolled hyperglycemia are typically in negative phosphate balance because of decreased phosphate intake, an acidosis-related shift of phosphate into the ECF when metabolic acidosis exists, and phosphaturia caused by osmotic diuresis. Despite phosphate depletion, the serum phosphate concentration at presentation is usually normal or even high because both insulin deficiency and metabolic acidosis cause a shift of phosphate out of the cells and as a result of ECF volume contraction [
         <a href="#rid53">
          53,54
         </a>
         ].
        </p>
        <p>
         This transcellular shift is reversed and the true state of phosphate balance is unmasked after treatment with insulin and volume expansion. In a review of 69 episodes of DKA, the mean serum phosphate concentration fell from 9.2 mg/dL (3 mmol/L) at presentation to 2.8 mg/dL (0.9 mmol/L) at 12 hours and, in some patients, to levels as low as 1 mg/dL (0.32 mmol/L) [
         <a href="#rid53">
          53
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1795.html" rel="external">
          "Diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults: Treatment", section on 'Phosphate depletion'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3174624">
         <span class="h3">
          Serum creatinine
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most patients with uncontrolled hyperglycemia have acute elevations in the BUN and serum creatinine concentration, which reflect the reduction in glomerular filtration rate induced by hypovolemia. High acetoacetate levels can also artifactually increase serum creatinine levels when certain colorimetric assays are utilized [
         <a href="#rid55">
          55
         </a>
         ]. However, most laboratories now utilize enzymatic assays, which are not affected by this artifact [
         <a href="#rid56">
          56
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H20">
         <span class="h3">
          Serum amylase and lipase
         </span>
         <span class="headingEndMark">
          —
         </span>
         Acute pancreatitis may precipitate or complicate DKA. Serum amylase and lipase are generally used to diagnose acute pancreatitis, but each of these enzymes is often elevated in patients with DKA who do not have any other clinical or radiological evidence of pancreatitis [
         <a href="#rid57">
          57-61
         </a>
         ]. Therefore, the diagnosis of pancreatitis in patients with DKA should be primarily based upon clinical findings and imaging. (See
         <a class="medical medical_review" href="/z/d/html/5652.html" rel="external">
          "Clinical manifestations and diagnosis of acute pancreatitis", section on 'Imaging'
         </a>
         .)
        </p>
        <p>
         The mechanisms for non-pancreatitis-associated hyperamylasemia and hyperlipasemia in DKA are not well understood, but the following observations have been made:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a review of 134 consecutive episodes of DKA in patients without evidence of acute pancreatitis on computed tomography (CT) scan, elevations of serum amylase and lipase (threefold or higher in some patients) were seen in 17 and 24 percent, respectively [
         <a href="#rid57">
          57
         </a>
         ]. Abdominal pain was present in 19 percent of the patients in this series.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The source of these nonspecific amylase elevations is most often salivary, though some may also be of pancreatic origin [
         <a href="#rid58">
          58,59,61
         </a>
         ]. The source of nonspecific lipase elevations is not known.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The rise in amylase correlates with pH and Posm, while the rise in lipase correlates only with Posm [
         <a href="#rid57">
          57
         </a>
         ]. Values peak within 24 hours of presentation [
         <a href="#rid61">
          61
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In 100 consecutive cases of DKA, 11 did have acute pancreatitis confirmed by CT scan. The most common causes of pancreatitis in these patients were hypertriglyceridemia and chronic alcohol intake [
         <a href="#rid62">
          62
         </a>
         ]. Two of the 10 evaluable patients (one was comatose) did not have abdominal pain.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H21">
         <span class="h3">
          Leukocytosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         The majority of patients with hyperglycemic emergencies present with leukocytosis, which is proportional to the degree of ketonemia [
         <a href="#rid6">
          6,63
         </a>
         ]. Leukocytosis unrelated to infection may occur as a result of hypercortisolemia and increased catecholamine secretion [
         <a href="#rid64">
          64
         </a>
         ]. However, a white blood cell count greater than 25,000/microL or more than 10 percent bands increases suspicion for infection and should be evaluated [
         <a href="#rid65">
          65
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H22">
         <span class="h3">
          Lipids
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with DKA or HHS may present with marked hyperlipidemia and lactescent serum. In a study of 13 patients with DKA, the mean plasma triglyceride and cholesterol levels on admission were 574 mg/dL (6.5 mmol/L) and 212 mg/dL (5.5 mmol/L), respectively [
         <a href="#rid66">
          66
         </a>
         ]. Triglycerides fell below 150 mg/dL (1.7 mmol/L) in 24 hours with insulin therapy.
        </p>
        <p>
         Lipolysis in DKA, and to a lesser extent in HHS, is due to insulin deficiency, combined with elevated levels of lipolytic hormones (catecholamines, growth hormone, corticotropin [ACTH], and glucagon). Lipolysis releases glycerol and free fatty acids into the circulation. High levels of serum fatty acids cause insulin resistance at both the peripheral and the hepatic level, and they serve as the substrate for ketoacid generation in hepatocyte mitochondria. Insulin is the most potent anti-lipolytic hormone.
        </p>
        <p class="headingAnchor" id="H5509770">
         <span class="h1">
          DIAGNOSTIC CRITERIA
         </span>
         <span class="headingEndMark">
          —
         </span>
         Diabetic ketoacidosis (DKA) and hyperosmolar hyperglycemic state (HHS) are distinguished by the absence of ketoacidosis and usually greater degree of hyperglycemia in HHS [
         <a href="#rid25">
          25,28,67
         </a>
         ]. The diagnostic criteria proposed by the American Diabetes Association (ADA) for mild, moderate, and severe DKA and HHS are shown in the table  (
         <a class="graphic graphic_table graphicRef72111" href="/z/d/graphic/72111.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         DKA is characterized by the triad of hyperglycemia, anion gap metabolic acidosis, and ketonemia. Metabolic acidosis is often the major finding. The serum glucose concentration is usually less than 800 mg/dL (44 mmol/L) and commonly between 350 to 500 mg/dL (19.4 to 27.8 mmol/L) [
         <a href="#rid15">
          15,28
         </a>
         ]. However, serum glucose concentrations may exceed 900 mg/dL (50 mmol/L) in patients with DKA who are comatose [
         <a href="#rid68">
          68
         </a>
         ]. In certain settings, such as starvation, pregnancy, treatment with insulin prior to arrival in the emergency department, or use of sodium-glucose co-transporter 2 (SGLT2) inhibitors, the glucose level may be mildly elevated or even normal.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In HHS, there is little or no ketoacid accumulation, the serum glucose concentration may exceed 1000 mg/dL (56 mmol/L), the plasma osmolality (Posm) may reach 380 mosmol/kg, and neurologic abnormalities are frequently present (including coma in 25 to 50 percent of cases) [
         <a href="#rid14">
          14,25,28
         </a>
         ]. Most patients with HHS have an admission pH &gt;7.30, a serum bicarbonate &gt;20 mEq/L, a serum glucose &gt;600 mg/dL (33.3 mmol/L), and test negative for ketones in serum and urine, although mild ketonemia may be present.
        </p>
        <p>
        </p>
        <p>
         Factors that contribute to the lesser degree of hyperglycemia in DKA, compared with HHS, are discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/1794.html" rel="external">
          "Diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults: Epidemiology and pathogenesis", section on 'Hyperglycemia'
         </a>
         .)
        </p>
        <p>
         Significant overlap between DKA and HHS has been reported in more than one-third of patients [
         <a href="#rid1">
          1,4,16,69
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H23">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The differential diagnosis of hyperglycemic crises includes other causes of ketosis, acidosis, hyperosmolality, and/or coma  (
         <a class="graphic graphic_table graphicRef72299" href="/z/d/graphic/72299.html" rel="external">
          table 5
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H24">
         <span class="h2">
          Alcoholic and fasting ketoacidosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Alcoholic ketoacidosis (AKA) and starvation ketosis are other causes of ketoacidosis. Low-carbohydrate diets can also precipitate ketoacidosis [
         <a href="#rid70">
          70
         </a>
         ]. Metabolic acidosis can be relatively severe in patients with AKA. However, when ketoacidosis develops as a result of starvation, it is usually relatively mild. Ketoacid levels with prolonged fasting rarely exceed 8 to 10 mEq/L, and the serum bicarbonate concentration is typically greater than 17 mEq/L [
         <a href="#rid71">
          71
         </a>
         ]. More severe ketoacidosis may develop with prolonged fasting in children and pregnant women [
         <a href="#rid72">
          72,73
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2337.html" rel="external">
          "Fasting ketosis and alcoholic ketoacidosis"
         </a>
         .)
        </p>
        <p>
         Ketoacidosis without hyperglycemia in a patient with chronic alcoholism is virtually diagnostic of AKA. Modest elevations in serum glucose in patients with alcoholic ketoacidosis may reflect underlying unrecognized diabetes or a catecholamine-mediated stress response [
         <a href="#rid74">
          74
         </a>
         ]. Measurement of glycated hemoglobin (A1C) can confirm chronic hyperglycemia.
        </p>
        <p class="headingAnchor" id="H25">
         <span class="h2">
          Anion gap acidosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Diabetic ketoacidosis (DKA) must be distinguished from other causes of high anion gap metabolic acidosis including lactic acidosis (which can rarely be associated with, or generated by,
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         , particularly in patients with impaired renal function);
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         or
         <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">
          acetaminophen
         </a>
         toxicity and poisoning with methanol, ethylene glycol, and propylene glycol; D-lactic acidosis; and advanced chronic kidney disease  (
         <a class="graphic graphic_table graphicRef77464" href="/z/d/graphic/77464.html" rel="external">
          table 6
         </a>
         ). Although none of these disorders cause ketoacidosis  (
         <a class="graphic graphic_table graphicRef72299" href="/z/d/graphic/72299.html" rel="external">
          table 5
         </a>
         ), several different types of acidosis may coexist, especially lactic acid and ketoacidosis. (See
         <a class="medical medical_review" href="/z/d/html/2291.html" rel="external">
          "Approach to the adult with metabolic acidosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4566263">
         <span class="h2">
          Metabolic encephalopathy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Toxic metabolic encephalopathy is usually a consequence of systemic illness, and its causes are diverse. In patients with diabetes, both severe hypoglycemia and severe hyperglycemia can result in coma. Measurement of fingerstick (capillary) or plasma glucose may be diagnostic  (
         <a class="graphic graphic_table graphicRef72299" href="/z/d/graphic/72299.html" rel="external">
          table 5
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/1661.html" rel="external">
          "Acute toxic-metabolic encephalopathy in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3370866680">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/113400.html" rel="external">
          "Society guideline links: Hyperglycemic emergencies"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H24146964">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (see
         <a class="medical medical_basics" href="/z/d/html/17051.html" rel="external">
          "Patient education: Diabetic ketoacidosis (The Basics)"
         </a>
         and
         <a class="medical medical_basics" href="/z/d/html/83155.html" rel="external">
          "Patient education: Hyperosmolar hyperglycemic state (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H26">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Precipitating factors
         </strong>
         – A precipitating event can usually be identified in patients with DKA or HHS. The most common are infection (eg, pneumonia, urinary tract infection, COVID-19) and discontinuation of, or inadequate, insulin therapy  (
         <a class="graphic graphic_table graphicRef64374" href="/z/d/graphic/64374.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="local">
          'Precipitating factors'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical presentation
         </strong>
         – Neurologic symptoms, which may include focal findings, are more often seen in HHS and primarily occur when the effective plasma osmolality (Posm) is greater than 320 to 330 mosmol/kg. The presence of stupor or coma in diabetic patients with an effective Posm below 320 mosmol/kg demands immediate consideration of other causes of the mental status change. Abdominal pain is common in DKA, but not in HHS, and requires evaluation if it does not resolve with treatment of the acidosis. Infection can occur without fever. (See
         <a class="local">
          'Clinical presentation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnostic evaluation
         </strong>
         – The initial evaluation of patients with hyperglycemic crises should include assessment of cardiorespiratory status, volume status, and mental status  (
         <a class="graphic graphic_table graphicRef57723" href="/z/d/graphic/57723.html" rel="external">
          table 3
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The initial laboratory evaluation of a patient with suspected DKA or HHS should include determination of serum glucose; electrolytes (with calculation of the anion gap), blood urea nitrogen (BUN), and plasma creatinine; complete blood count (CBC) with differential; urinalysis and urine ketones by dipstick; Posm; serum ketones; arterial blood gas (if the serum bicarbonate is substantially reduced or hypoxia is suspected); and electrocardiogram. (See
         <a class="local">
          'Diagnostic evaluation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Laboratory findings
         </strong>
         –
         <strong>
         </strong>
         Diabetic ketoacidosis (DKA) and hyperosmolar hyperglycemic state (HHS) primarily differ according to the presence of ketoacidosis and the degree of hyperglycemia  (
         <a class="graphic graphic_table graphicRef72111" href="/z/d/graphic/72111.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Serum ketones
         </strong>
         – Three ketone bodies are produced in DKA: one ketoacid (acetoacetic acid), one hydroxyacid (beta-hydroxybutyric acid), and one neutral ketone (acetone). Urine ketone bodies are detected by a dipstick with
         <a class="drug drug_general" data-topicid="9707" href="/z/d/drug information/9707.html" rel="external">
          nitroprusside
         </a>
         tests, while serum ketones can be detected by direct assay of beta-hydroxybutyrate levels or with a nitroprusside test. Direct assay of beta-hydroxybutyrate levels is preferred. (See
         <a class="local">
          'Serum ketones'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Anion gap metabolic acidosis
         </strong>
         – Patients with DKA usually present with a serum anion gap greater than 20 mEq/L. However, the increase in anion gap is variable, being determined by several factors: the rate and duration of ketoacid production, the rate of metabolism of the ketoacids and their loss in the urine, and the volume of distribution of the ketoacid anions. (See
         <a class="local">
          'Anion gap metabolic acidosis'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/1794.html" rel="external">
          "Diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults: Epidemiology and pathogenesis", section on 'Anion gap metabolic acidosis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Serum sodium
         </strong>
         – Most patients with DKA and HHS are mildly hyponatremic, but patients who have a marked osmotic diuresis may have a normal or even elevated serum sodium (Na) concentration. The serum Na concentration in DKA and HHS reflects the balance between the dilutional effect of water moving out of cells in response to the hyperglycemia-induced increase in serum osmolality and the increase in electrolyte-free water excretion due to the glucosuria-induced osmotic diuresis  (
         <a class="graphic graphic_table graphicRef76060" href="/z/d/graphic/76060.html" rel="external">
          table 4
         </a>
         ). (See
         <a class="local">
          'Serum sodium'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/1794.html" rel="external">
          "Diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults: Epidemiology and pathogenesis", section on 'Plasma osmolality and sodium'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Potassium deficit
         </strong>
         – Patients with DKA or HHS have a potassium deficit that averages 300 to 600 mEq. Despite this deficit, the serum potassium concentration is often elevated at presentation, as both insulin deficiency and hyperosmolality result in potassium movement out of the cells into the extracellular fluid (ECF). Insulin therapy lowers the potassium concentration and may cause severe hypokalemia, particularly in patients with a normal or low serum potassium concentration at presentation. Thus, careful monitoring and timely administration of potassium supplementation are essential. (See
         <a class="local">
          'Serum potassium'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Amylase and lipase
         </strong>
         – Serum amylase and lipase levels are elevated in 15 to 25 percent of patients with DKA and, in most cases, do not reflect acute pancreatitis. The diagnosis of pancreatitis should be based upon clinical findings and confirmed by imaging. (See
         <a class="local">
          'Serum amylase and lipase'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnostic criteria
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          DKA
         </strong>
         – DKA is diagnosed when the triad of hyperglycemia, anion gap metabolic acidosis, and ketonemia is present. Metabolic acidosis is often the major finding  (
         <a class="graphic graphic_table graphicRef72111" href="/z/d/graphic/72111.html" rel="external">
          table 1
         </a>
         ). The serum glucose concentration is usually less than 800 mg/dL (44 mmol/L) and generally between 350 to 500 mg/dL (19.4 to 27.8 mmol/L).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          HHS
         </strong>
         – In HHS, there is little or no ketoacid accumulation, the serum glucose concentration may exceed 1000 mg/dL (56 mmol/L), the effective Posm is &gt;320 mosmol/kg, and neurologic abnormalities are frequently present (including coma in 25 to 50 percent of cases)  (
         <a class="graphic graphic_table graphicRef72111" href="/z/d/graphic/72111.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="local">
          'Diagnostic criteria'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Differential diagnosis
         </strong>
         – Ketoacidosis may also be caused by alcohol abuse or fasting. Other causes of an anion gap acidosis include lactic acidosis, ingestion of drugs such as
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         , methanol, and ethylene glycol, and advanced chronic kidney disease. (See
         <a class="local">
          'Differential diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3347572822">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Abbas Kitabchi, PhD, MD, FACP, MACE (deceased), who contributed to earlier versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li class="breakAll">
          Kitabchi AE, Razavi L.Hyperglycemic Crises: Diabetic Ketoacidosis (DKA), And Hyperglycemic Hyperosmolar State (HHS). In: http://www.endotext.org/diabetes/diabetes24/diabetesframe24.htm (Accessed on January 30, 2013).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Randall L, Begovic J, Hudson M, et al. Recurrent diabetic ketoacidosis in inner-city minority patients: behavioral, socioeconomic, and psychosocial factors. Diabetes Care 2011; 34:1891.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wachtel TJ, Tetu-Mouradjian LM, Goldman DL, et al. Hyperosmolarity and acidosis in diabetes mellitus: a three-year experience in Rhode Island. J Gen Intern Med 1991; 6:495.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wachtel TJ. The diabetic hyperosmolar state. Clin Geriatr Med 1990; 6:797.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wachtel TJ, Silliman RA, Lamberton P. Prognostic factors in the diabetic hyperosmolar state. J Am Geriatr Soc 1987; 35:737.
          </a>
         </li>
         <li class="breakAll">
          Kitabchi AE, Murphy MB. Consequences of insulin deficiency. In: Atlas of Diabetes, 4th, Skyler J (Ed), Springer US, New York 2012. p.39.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005; 19 Suppl 1:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taylor SI, Blau JE, Rother KI. SGLT2 Inhibitors May Predispose to Ketoacidosis. J Clin Endocrinol Metab 2015; 100:2849.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Warner EA, Greene GS, Buchsbaum MS, et al. Diabetic ketoacidosis associated with cocaine use. Arch Intern Med 1998; 158:1799.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nyenwe EA, Loganathan RS, Blum S, et al. Active use of cocaine: an independent risk factor for recurrent diabetic ketoacidosis in a city hospital. Endocr Pract 2007; 13:22.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Polonsky WH, Anderson BJ, Lohrer PA, et al. Insulin omission in women with IDDM. Diabetes Care 1994; 17:1178.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peden NR, Braaten JT, McKendry JB. Diabetic ketoacidosis during long-term treatment with continuous subcutaneous insulin infusion. Diabetes Care 1984; 7:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pańkowska E, Błazik M, Dziechciarz P, et al. Continuous subcutaneous insulin infusion vs. multiple daily injections in children with type 1 diabetes: a systematic review and meta-analysis of randomized control trials. Pediatr Diabetes 2009; 10:52.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Daugirdas JT, Kronfol NO, Tzamaloukas AH, Ing TS. Hyperosmolar coma: cellular dehydration and the serum sodium concentration. Ann Intern Med 1989; 110:855.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fulop M, Tannenbaum H, Dreyer N. Ketotic hyperosmolar coma. Lancet 1973; 2:635.
          </a>
         </li>
         <li class="breakAll">
          Kitabchi AE, Fisher JN. Insulin therapy of diabetic ketoacidosis: Physiologic versus pharmacologic doses of insulin and their routes of administration. In: Handbook of Diabetes Mellitus, Brownlee M (Ed), Garland ATPM Press, New York 1981. p.95.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lorber D. Nonketotic hypertonicity in diabetes mellitus. Med Clin North Am 1995; 79:39.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maccario M. Neurological dysfunction associated with nonketotic hyperglycemia. Arch Neurol 1968; 19:525.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guisado R, Arieff AI. Neurologic manifestations of diabetic comas: correlation with biochemical alterations in the brain. Metabolism 1975; 24:665.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lavin PJ. Hyperglycemic hemianopia: a reversible complication of non-ketotic hyperglycemia. Neurology 2005; 65:616.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harden CL, Rosenbaum DH, Daras M. Hyperglycemia presenting with occipital seizures. Epilepsia 1991; 32:215.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nyenwe EA, Razavi LN, Kitabchi AE, et al. Acidosis: the prime determinant of depressed sensorium in diabetic ketoacidosis. Diabetes Care 2010; 33:1837.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Malone ML, Gennis V, Goodwin JS. Characteristics of diabetic ketoacidosis in older versus younger adults. J Am Geriatr Soc 1992; 40:1100.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Umpierrez G, Freire AX. Abdominal pain in patients with hyperglycemic crises. J Crit Care 2002; 17:63.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kitabchi AE, Umpierrez GE, Miles JM, Fisher JN. Hyperglycemic crises in adult patients with diabetes. Diabetes Care 2009; 32:1335.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barrett EJ, DeFronzo RA. Diabetic ketoacidosis: diagnosis and treatment. Hosp Pract (Off Ed) 1984; 19:89.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kitabchi AE, Umpierrez GE, Murphy MB, et al. Management of hyperglycemic crises in patients with diabetes. Diabetes Care 2001; 24:131.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arieff AI, Carroll HJ. Nonketotic hyperosmolar coma with hyperglycemia: clinical features, pathophysiology, renal function, acid-base balance, plasma-cerebrospinal fluid equilibria and the effects of therapy in 37 cases. Medicine (Baltimore) 1972; 51:73.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Munro JF, Campbell IW, McCuish AC, Duncan LJ. Euglycaemic diabetic ketoacidosis. Br Med J 1973; 2:578.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burge MR, Hardy KJ, Schade DS. Short-term fasting is a mechanism for the development of euglycemic ketoacidosis during periods of insulin deficiency. J Clin Endocrinol Metab 1993; 76:1192.
          </a>
         </li>
         <li class="breakAll">
          Eisenbarth GS, Polonsky KS, Buse JB. Type 1 diabetes mellitus: Acute diabetic emergencies: Diabetic ketoacidosis. In: Williams Textbook of Endocrinology, Larsen PR, Kronenberg HM, Melmed S, Polonsky KS (Eds), Elsevier Science, Philadelphia 2003. p.1500.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Qiu H, Novikov A, Vallon V. Ketosis and diabetic ketoacidosis in response to SGLT2 inhibitors: Basic mechanisms and therapeutic perspectives. Diabetes Metab Res Rev 2017; 33.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sheikh-Ali M, Karon BS, Basu A, et al. Can serum beta-hydroxybutyrate be used to diagnose diabetic ketoacidosis? Diabetes Care 2008; 31:643.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Laffel L. Ketone bodies: a review of physiology, pathophysiology and application of monitoring to diabetes. Diabetes Metab Res Rev 1999; 15:412.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wiggam MI, O'Kane MJ, Harper R, et al. Treatment of diabetic ketoacidosis using normalization of blood 3-hydroxybutyrate concentration as the endpoint of emergency management. A randomized controlled study. Diabetes Care 1997; 20:1347.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Porter WH, Yao HH, Karounos DG. Laboratory and clinical evaluation of assays for beta-hydroxybutyrate. Am J Clin Pathol 1997; 107:353.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fulop M, Murthy V, Michilli A, et al. Serum beta-hydroxybutyrate measurement in patients with uncontrolled diabetes mellitus. Arch Intern Med 1999; 159:381.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith SW, Manini AF, Szekely T, Hoffman RS. Bedside detection of urine beta-hydroxybutyrate in diagnosing metabolic acidosis. Acad Emerg Med 2008; 15:751.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bektas F, Eray O, Sari R, Akbas H. Point of care blood ketone testing of diabetic patients in the emergency department. Endocr Res 2004; 30:395.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           DeFronzo RA, Matzuda M, Barret E. Diabetic ketoacidosis: a combined metabolic-nephrologic approach to therapy. Diabetes Rev 1994; 2:209.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adrogué HJ, Lederer ED, Suki WN, Eknoyan G. Determinants of plasma potassium levels in diabetic ketoacidosis. Medicine (Baltimore) 1986; 65:163.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khardori R, Soler NG. Hyperosmolar hyperglycemic nonketotic syndrome. Report of 22 cases and brief review. Am J Med 1984; 77:899.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Phillips PA, Bretherton M, Johnston CI, Gray L. Reduced osmotic thirst in healthy elderly men. Am J Physiol 1991; 261:R166.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaminska ES, Pourmotabbed G. Spurious laboratory values in diabetic ketoacidosis and hyperlipidemia. Am J Emerg Med 1993; 11:77.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rumbak MJ, Hughes TA, Kitabchi AE. Pseudonormoglycemia in diabetic ketoacidosis with elevated triglycerides. Am J Emerg Med 1991; 9:61.
          </a>
         </li>
         <li class="breakAll">
          Emmett M. Case 6: Diabetes and Acidosis. In: NephSAP: Nephrology Self-Assessment Program: Fluid, Electrolyte, and Acid-Base Disturbances, Sterns RH, Emmett M (Eds), The American Society of Nephrology 2013. Vol 12, No 3, p.191.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Graber ML, Quigg RJ, Stempsey WE, Weis S. Spurious hyperchloremia and decreased anion gap in hyperlipidemia. Ann Intern Med 1983; 98:607.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kreisberg RA. Diabetic ketoacidosis: new concepts and trends in pathogenesis and treatment. Ann Intern Med 1978; 88:681.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abramson E, Arky R. Diabetic acidosis with initial hypokalemia. Therapeutic implications. JAMA 1966; 196:401.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Murthy K, Harrington JT, Siegel RD. Profound hypokalemia in diabetic ketoacidosis: a therapeutic challenge. Endocr Pract 2005; 11:331.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arora S, Cheng D, Wyler B, Menchine M. Prevalence of hypokalemia in ED patients with diabetic ketoacidosis. Am J Emerg Med 2012; 30:481.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Atchley DW, Loeb RF, Richards DW, et al. ON DIABETIC ACIDOSIS: A Detailed Study of Electrolyte Balances Following the Withdrawal and Reestablishment of Insulin Therapy. J Clin Invest 1933; 12:297.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kebler R, McDonald FD, Cadnapaphornchai P. Dynamic changes in serum phosphorus levels in diabetic ketoacidosis. Am J Med 1985; 79:571.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shen T, Braude S. Changes in serum phosphate during treatment of diabetic ketoacidosis: predictive significance of severity of acidosis on presentation. Intern Med J 2012; 42:1347.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Molitch ME, Rodman E, Hirsch CA, Dubinsky E. Spurious serum creatinine elevations in ketoacidosis. Ann Intern Med 1980; 93:280.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kemperman FA, Weber JA, Gorgels J, et al. The influence of ketoacids on plasma creatinine assays in diabetic ketoacidosis. J Intern Med 2000; 248:511.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yadav D, Nair S, Norkus EP, Pitchumoni CS. Nonspecific hyperamylasemia and hyperlipasemia in diabetic ketoacidosis: incidence and correlation with biochemical abnormalities. Am J Gastroenterol 2000; 95:3123.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Warshaw AL, Feller ER, Lee KH. On the cause of raised serum-amylase in diabetic ketoacidosis. Lancet 1977; 1:929.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vinicor F, Lehrner LM, Karn RC, Merritt AD. Hyperamylasemia in diabetic ketoacidosis: sources and significance. Ann Intern Med 1979; 91:200.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vantyghem MC, Haye S, Balduyck M, et al. Changes in serum amylase, lipase and leukocyte elastase during diabetic ketoacidosis and poorly controlled diabetes. Acta Diabetol 1999; 36:39.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kjaergaard JJ, Salling N, Magid E, Ditzel J. Serum amylase during recovery from diabetic ketoacidosis. Diabete Metab 1984; 10:25.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nair S, Yadav D, Pitchumoni CS. Association of diabetic ketoacidosis and acute pancreatitis: observations in 100 consecutive episodes of DKA. Am J Gastroenterol 2000; 95:2795.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stentz FB, Umpierrez GE, Cuervo R, Kitabchi AE. Proinflammatory cytokines, markers of cardiovascular risks, oxidative stress, and lipid peroxidation in patients with hyperglycemic crises. Diabetes 2004; 53:2079.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nematollahi LR, Taheri E, Larijani B, et al. Catecholamine-induced leukocytosis in acute hypoglycemic stress. J Investig Med 2007; 55:S262.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Slovis CM, Mork VG, Slovis RJ, Bain RP. Diabetic ketoacidosis and infection: leukocyte count and differential as early predictors of serious infection. Am J Emerg Med 1987; 5:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weidman SW, Ragland JB, Fisher JN Jr, et al. Effects of insulin on plasma lipoproteins in diabetic ketoacidosis: evidence for a change in high density lipoprotein composition during treatment. J Lipid Res 1982; 23:171.
          </a>
         </li>
         <li class="breakAll">
          Rose BD, Post TW. Clinical Physiology of Acid-Base and Electrolyte Disorders, 5th, McGraw-Hill, New York 2001. p.809-815.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morris LR, Kitabchi AE. Efficacy of low-dose insulin therapy for severely obtunded patients in diabetic ketoacidosis. Diabetes Care 1980; 3:53.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Szeto CC, Li KY, Ko GT, et al. Acromegaly in a woman presenting with diabetic ketoacidosis and insulin resistance. Int J Clin Pract 1997; 51:476.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shah P, Isley WL. Ketoacidosis during a low-carbohydrate diet. N Engl J Med 2006; 354:97.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reichard GA Jr, Owen OE, Haff AC, et al. Ketone-body production and oxidation in fasting obese humans. J Clin Invest 1974; 53:508.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cahill GF Jr. Fuel metabolism in starvation. Annu Rev Nutr 2006; 26:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mahoney CA. Extreme gestational starvation ketoacidosis: case report and review of pathophysiology. Am J Kidney Dis 1992; 20:276.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wrenn KD, Slovis CM, Minion GE, Rutkowski R. The syndrome of alcoholic ketoacidosis. Am J Med 1991; 91:119.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 1792 Version 34.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="http://www.endotext.org/diabetes/diabetes24/diabetesframe24.htm" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Kitabchi AE, Razavi L.Hyperglycemic Crises: Diabetic Ketoacidosis (DKA), And Hyperglycemic Hyperosmolar State (HHS). In: http://www.endotext.org/diabetes/diabetes24/diabetesframe24.htm (Accessed on January 30, 2013).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21775761" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Recurrent diabetic ketoacidosis in inner-city minority patients: behavioral, socioeconomic, and psychosocial factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1765864" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Hyperosmolarity and acidosis in diabetes mellitus: a three-year experience in Rhode Island.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2224747" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : The diabetic hyperosmolar state.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3611564" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Prognostic factors in the diabetic hyperosmolar state.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3611564" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Prognostic factors in the diabetic hyperosmolar state.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15998156" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26086329" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : SGLT2 Inhibitors May Predispose to Ketoacidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9738609" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Diabetic ketoacidosis associated with cocaine use.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17360297" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Active use of cocaine: an independent risk factor for recurrent diabetic ketoacidosis in a city hospital.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7821139" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Insulin omission in women with IDDM.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6423352" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Diabetic ketoacidosis during long-term treatment with continuous subcutaneous insulin infusion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18761648" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Continuous subcutaneous insulin infusion vs. multiple daily injections in children with type 1 diabetes: a systematic review and meta-analysis of randomized control trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2655518" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Hyperosmolar coma: cellular dehydration and the serum sodium concentration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4125618" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Ketotic hyperosmolar coma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4125618" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Ketotic hyperosmolar coma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7808094" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Nonketotic hypertonicity in diabetes mellitus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5684300" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Neurological dysfunction associated with nonketotic hyperglycemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/805337" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Neurologic manifestations of diabetic comas: correlation with biochemical alterations in the brain.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16116129" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Hyperglycemic hemianopia: a reversible complication of non-ketotic hyperglycemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2004625" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Hyperglycemia presenting with occipital seizures.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20484127" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Acidosis: the prime determinant of depressed sensorium in diabetic ketoacidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1401693" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Characteristics of diabetic ketoacidosis in older versus younger adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12040551" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Abdominal pain in patients with hyperglycemic crises.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19564476" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Hyperglycemic crises in adult patients with diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6425326" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Diabetic ketoacidosis: diagnosis and treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11194218" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Management of hyperglycemic crises in patients with diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5013637" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Nonketotic hyperosmolar coma with hyperglycemia: clinical features, pathophysiology, renal function, acid-base balance, plasma-cerebrospinal fluid equilibria and the effects of therapy in 37 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4197425" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Euglycaemic diabetic ketoacidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8496310" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Short-term fasting is a mechanism for the development of euglycemic ketoacidosis during periods of insulin deficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8496310" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Short-term fasting is a mechanism for the development of euglycemic ketoacidosis during periods of insulin deficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28099783" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Ketosis and diabetic ketoacidosis in response to SGLT2 inhibitors: Basic mechanisms and therapeutic perspectives.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18184896" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Can serum beta-hydroxybutyrate be used to diagnose diabetic ketoacidosis?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10634967" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Ketone bodies: a review of physiology, pathophysiology and application of monitoring to diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9283776" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Treatment of diabetic ketoacidosis using normalization of blood 3-hydroxybutyrate concentration as the endpoint of emergency management. A randomized controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9052387" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Laboratory and clinical evaluation of assays for beta-hydroxybutyrate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10030312" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Serum beta-hydroxybutyrate measurement in patients with uncontrolled diabetes mellitus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18637083" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Bedside detection of urine beta-hydroxybutyrate in diagnosing metabolic acidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15554356" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Point of care blood ketone testing of diabetic patients in the emergency department.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Diabetic ketoacidosis: a combined metabolic-nephrologic approach to therapy
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3084904" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Determinants of plasma potassium levels in diabetic ketoacidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6496545" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Hyperosmolar hyperglycemic nonketotic syndrome. Report of 22 cases and brief review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1858944" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Reduced osmotic thirst in healthy elderly men.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8447878" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Spurious laboratory values in diabetic ketoacidosis and hyperlipidemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1898702" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Pseudonormoglycemia in diabetic ketoacidosis with elevated triglycerides.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1898702" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Pseudonormoglycemia in diabetic ketoacidosis with elevated triglycerides.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6846974" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Spurious hyperchloremia and decreased anion gap in hyperlipidemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/417652" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Diabetic ketoacidosis: new concepts and trends in pathogenesis and treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5952215" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Diabetic acidosis with initial hypokalemia. Therapeutic implications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16191494" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Profound hypokalemia in diabetic ketoacidosis: a therapeutic challenge.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21316179" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Prevalence of hypokalemia in ED patients with diabetic ketoacidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16694129" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : ON DIABETIC ACIDOSIS: A Detailed Study of Electrolyte Balances Following the Withdrawal and Reestablishment of Insulin Therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3933341" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Dynamic changes in serum phosphorus levels in diabetic ketoacidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23252999" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Changes in serum phosphate during treatment of diabetic ketoacidosis: predictive significance of severity of acidosis on presentation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6773457" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Spurious serum creatinine elevations in ketoacidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11155144" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : The influence of ketoacids on plasma creatinine assays in diabetic ketoacidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11095328" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Nonspecific hyperamylasemia and hyperlipasemia in diabetic ketoacidosis: incidence and correlation with biochemical abnormalities.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/67388" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : On the cause of raised serum-amylase in diabetic ketoacidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/111594" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Hyperamylasemia in diabetic ketoacidosis: sources and significance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10436251" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Changes in serum amylase, lipase and leukocyte elastase during diabetic ketoacidosis and poorly controlled diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6202570" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Serum amylase during recovery from diabetic ketoacidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11051350" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Association of diabetic ketoacidosis and acute pancreatitis: observations in 100 consecutive episodes of DKA.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15277389" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Proinflammatory cytokines, markers of cardiovascular risks, oxidative stress, and lipid peroxidation in patients with hyperglycemic crises.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Catecholamine-induced leukocytosis in acute hypoglycemic stress
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3101715" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Diabetic ketoacidosis and infection: leukocyte count and differential as early predictors of serious infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6799600" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Effects of insulin on plasma lipoproteins in diabetic ketoacidosis: evidence for a change in high density lipoprotein composition during treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6799600" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Effects of insulin on plasma lipoproteins in diabetic ketoacidosis: evidence for a change in high density lipoprotein composition during treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6773727" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Efficacy of low-dose insulin therapy for severely obtunded patients in diabetic ketoacidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9536592" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Acromegaly in a woman presenting with diabetic ketoacidosis and insulin resistance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16394313" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Ketoacidosis during a low-carbohydrate diet.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11344564" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Ketone-body production and oxidation in fasting obese humans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16848698" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Fuel metabolism in starvation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1519609" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Extreme gestational starvation ketoacidosis: case report and review of pathophysiology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1867237" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : The syndrome of alcoholic ketoacidosis.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
